دورية أكاديمية
Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.
| العنوان: | Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis. |
|---|---|
| المؤلفون: | de Oliveira PSS; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil., da Paixão ABF; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil., da Rocha Junior LF; Rheumatology Service, Clinical Hospital, UFPE, Recife, PE, Brazil., Branco Pinto Duarte AL; Rheumatology Service, Clinical Hospital, UFPE, Recife, PE, Brazil., Pereira MC; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil., Barreto de Melo Rêgo MJ; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil. Electronic address: moacyr.rego@gmail.com., da Rocha Pitta I; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil., da Rocha Pitta MG; Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Suely-Galdino Therapeutic Innovation Research Center (NUPIT-SG), Federal University of Pernambuco (UFPE), Recife, PE, Brazil. |
| المصدر: | Immunobiology [Immunobiology] 2020 May; Vol. 225 (3), pp. 151908. Date of Electronic Publication: 2020 Jan 30. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8002742 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3279 (Electronic) Linking ISSN: 01712985 NLM ISO Abbreviation: Immunobiology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Amsterdam : Elsevier Original Publication: Stuttgart ; New York, Fischer. |
| مواضيع طبية MeSH: | Atorvastatin/*pharmacology , Cytokines/*biosynthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology , Leukocytes, Mononuclear/*drug effects , Leukocytes, Mononuclear/*metabolism, Arthritis, Rheumatoid ; Cells, Cultured ; Humans ; Interleukin-10/biosynthesis ; Interleukin-17/biosynthesis ; Interleukin-6/biosynthesis ; Leukocytes, Mononuclear/immunology ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Tumor Necrosis Factors/biosynthesis |
| مستخلص: | Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint damage, and it may present with comorbidities at the systemic level. The Th1/Th2/Th17 CD4 + lymphocyte imbalance produces inflammatory cytokines, which begin to act, injuring joint tissue. Atorvastatin is a cholesterol- lowering drug with a range of biological effects including anti-inflammatory potential. Patients with rheumatoid arthritis who used statins exhibited clinical improvement. However, the mechanism is not fully understood. Therefore, we aimed to evaluate the RA immunomodulatory activity of atorvastatin. Methods: Peripheral blood mononuclear cells (PBMCs) of RA patients and healthy donors were exposed to atorvastatin in different concentrations following a cytotoxicity assay. Th1, Th2, and Th17 cytokines profiles were evaluated in the culture supernatant by cytometric bead array (CBA). Data were analyzed using the Wilcoxon test, and differences were considered significant when p < 0.05. Results: Atorvastatin showed no toxicity at the tested doses in RA PBMC cultures, and at 10μM, it showed the most significant results, reducing IL-17A (p = 0.002), TNF (p = 0.002), and IL-6 (p = 0.008) supernatant levels. The outcomes also revealed that only patients with more severe disease activity and those sensitive to corticoid treatments were responders to atorvastatin in vitro. Conclusion: These findings suggest the potential immunomodulatory action of atorvastatin as a mechanism in rheumatoid arthritis treatment. Competing Interests: Declaration of Competing Interest None. (Copyright © 2020. Published by Elsevier GmbH.) |
| فهرسة مساهمة: | Keywords: Clinical assessment; Cytokines; Inflammation; Joint; Statin |
| المشرفين على المادة: | 0 (Cytokines) 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) 0 (IL10 protein, human) 0 (IL17A protein, human) 0 (Interleukin-17) 0 (Interleukin-6) 0 (Tumor Necrosis Factors) 130068-27-8 (Interleukin-10) A0JWA85V8F (Atorvastatin) |
| تواريخ الأحداث: | Date Created: 20200214 Date Completed: 20210806 Latest Revision: 20210806 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.imbio.2020.151908 |
| PMID: | 32051095 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1878-3279 |
|---|---|
| DOI: | 10.1016/j.imbio.2020.151908 |